Other promising targets of mAbs are CD52 (Alemtuzumab, in B-ALL precursors), CD23 (Lumiliximab, in CLL), CD22 (Inotuzumab Ozogamicin and Epratuzumab, in precursors and mature B-ALL), and CD33 (Gemtuzumab ozogamicin, in AML) [39,96,97]. This evidence concerns the gene CD33 and acute myeloid leukemia.